Gilead Sciences is collaborating with Ideaya Biosciences, providing Trodelvy supply to support clinical trials.
1 report, 1 independent
Updated Sep 4
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Gilead Sciences is collaborating with Ideaya Biosciences, providing Trodelvy supply to support clinical trials.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Ideaya Biosciences (United States)
company in South San Francisco, United States
-
Gilead Sciences
American company
- Required regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.
- A pilot program is underway involving the federal government, Benue State, and Gilead Sciences, with the state participating in the drug supply management.
Related events
Coverage
Newest first; wire copies grouped- PR NewswireIDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer SOUTH SA